Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer Blackrock
Entity holding fund iShares IV Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF Ticker BTEC(USD) LSE
ETF Ticker BTEK(GBP) LSE
ETF Ticker 2B70(EUR) F
ETF Ticker 2B70.DE(EUR) CXE
ETF Ticker BTEC.LS(USD) CXE
ETF Ticker BTEK.LS(GBP) CXE
ETF Ticker BTEC.L(GBP) LSE
ETF Ticker BTEK.L(GBP) LSE

Holdings detail for ANIP

Stock Name	ANI Pharmaceuticals Inc
Ticker	ANIP(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US00182C1036
LEI	5493000T6CXTND40YH31

Show aggregate ANIP holdings

News associated with ANIP

HC Wainwright Forecasts Strong Price Appreciation for ANI Pharmaceuticals (NASDAQ:ANIP) Stock: ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) had its target price increased by HC Wainwright from $93.00 to $121.00 in a report issued on Wednesday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 24.13% from the stock’s […] - 2025-09-19 03:05:01
ANI Pharmaceuticals (NASDAQ:ANIP) Reaches New 12-Month High Following Analyst Upgrade: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) hit a new 52-week high on Tuesday after Guggenheim raised their price target on the stock from $86.00 to $114.00. Guggenheim currently has a buy rating on the stock. ANI Pharmaceuticals traded as high as $96.66 and last traded at $96.30, with a volume of 66131 shares […] - 2025-09-10 02:20:55
ANI Pharmaceuticals (NASDAQ:ANIP) COO Sells $4,618,078.50 in Stock: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) COO Muthusamy Shanmugam sold 52,990 shares of the firm’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $87.15, for a total transaction of $4,618,078.50. Following the completion of the sale, the chief operating officer directly owned 531,920 shares […] - 2025-08-21 05:19:08
Deutsche Bank AG Trims Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP): Deutsche Bank AG trimmed its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 6.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 218,086 shares of the specialty pharmaceutical company’s stock after selling 14,242 shares during […] - 2025-08-15 05:15:08
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Expected to Rise, Truist Financial Analyst Says: ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) had its target price raised by investment analysts at Truist Financial from $65.00 to $77.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “hold” rating on the specialty pharmaceutical company’s stock. Truist Financial’s target price suggests a potential downside of 12.84% […] - 2025-08-13 02:46:43
Victory Capital Management Inc. Has $1.13 Million Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP): Victory Capital Management Inc. grew its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 22.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 16,863 shares of the specialty pharmaceutical company’s stock after buying an additional 3,086 shares during the period. Victory Capital […] - 2025-07-31 05:28:47
Bank of New York Mellon Corp Reduces Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP): Bank of New York Mellon Corp lessened its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 3.7% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 119,262 shares of the specialty pharmaceutical company’s stock after selling 4,570 shares during the quarter. Bank of New York Mellon Corp’s holdings in ANI Pharmaceuticals […] - 2025-07-23 04:30:44
Louisiana State Employees Retirement System Has $522,000 Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP): Louisiana State Employees Retirement System cut its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 2.5% during the first quarter, Holdings Channel.com reports. The firm owned 7,800 shares of the specialty pharmaceutical company’s stock after selling 200 shares during the quarter. Louisiana State Employees Retirement System’s holdings in ANI Pharmaceuticals were worth $522,000 […] - 2025-07-21 05:16:50
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $78.88 Consensus Target Price from Analysts: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has been assigned an average recommendation of “Buy” from the nine ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the […] - 2025-07-18 02:23:01
GAMMA Investing LLC Has $95,000 Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP): GAMMA Investing LLC lifted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 163.8% during the first quarter, Holdings Channel.com reports. The firm owned 1,419 shares of the specialty pharmaceutical company’s stock after purchasing an additional 881 shares during the period. GAMMA Investing LLC’s holdings in ANI Pharmaceuticals were worth $95,000 […] - 2025-07-07 04:17:14
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $80.13 Average PT from Brokerages: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received an average recommendation of “Buy” from the nine brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The […] - 2025-06-23 02:14:07
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $80.13 Average Target Price from Analysts: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received a consensus recommendation of “Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-05-29 02:27:28
Surprising Analyst 12-Month Target For VIOO: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-13 08:45:24
Comerica Bank Has $1.04 Million Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP): Comerica Bank lowered its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 30.1% in the 4th quarter, HoldingsChannel reports. The firm owned 18,830 shares of the specialty pharmaceutical company’s stock after selling 8,099 shares during the period. Comerica Bank’s holdings in ANI Pharmaceuticals were worth $1,041,000 at the end of the […] - 2025-05-13 05:42:52
MetLife Investment Management LLC Has $630,000 Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP): MetLife Investment Management LLC increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 6.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,397 shares of the specialty pharmaceutical company’s stock after buying an additional 675 […] - 2025-05-05 06:01:03
Dimensional Fund Advisors LP Raises Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP): Dimensional Fund Advisors LP raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 4.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 685,730 shares of the specialty pharmaceutical company’s stock after purchasing an additional 30,420 […] - 2025-05-05 05:20:53
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Buy” from Analysts: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has been given an average rating of “Buy” by the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to […] - 2025-05-01 02:12:50
Legal & General Group Plc Acquires 2,585 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP): Legal & General Group Plc increased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 5.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 48,425 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,585 shares during the quarter. Legal & General Group Plc’s holdings in ANI […] - 2025-04-24 05:18:54
Invesco Ltd. Lowers Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP): Invesco Ltd. lowered its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 10.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 197,545 shares of the specialty pharmaceutical company’s stock after selling 22,814 shares during the quarter. Invesco […] - 2025-04-23 05:08:58
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Expected to Rise, Truist Financial Analyst Says: ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) had its target price upped by analysts at Truist Financial from $62.00 to $65.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “hold” rating on the specialty pharmaceutical company’s stock. Truist Financial’s price target points to a potential downside of 5.73% from the company’s […] - 2025-04-23 02:42:48
Vanguard Group Inc. Sells 33,739 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP): Vanguard Group Inc. reduced its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 2.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,314,372 shares of the specialty pharmaceutical company’s stock after selling 33,739 shares during the quarter. Vanguard […] - 2025-04-11 04:52:47
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by StockNews.com: ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday. Other equities analysts have also recently issued reports about the stock. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on […] - 2025-04-10 03:13:02
Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) PT at $79.75: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The […] - 2025-04-09 02:04:49
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Position Trimmed by Corebridge Financial Inc.: Corebridge Financial Inc. reduced its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 7.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,778 shares of the specialty pharmaceutical company’s stock after selling 762 shares during the quarter. Corebridge […] - 2025-04-08 04:27:01
Thrivent Financial for Lutherans Reduces Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP): Thrivent Financial for Lutherans trimmed its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 1.5% in the 4th quarter, HoldingsChannel reports. The firm owned 12,828 shares of the specialty pharmaceutical company’s stock after selling 200 shares during the quarter. Thrivent Financial for Lutherans’ holdings in ANI Pharmaceuticals were worth $709,000 as of its […] - 2025-04-03 04:16:46
ANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Analysts at Jefferies Financial Group: Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) in a report released on Friday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $80.00 target price on the specialty pharmaceutical company’s stock. Several other analysts have also recently commented on ANIP. StockNews.com cut shares of ANI […] - 2025-03-17 04:26:54
JPMorgan Chase & Co. Begins Coverage on ANI Pharmaceuticals (NASDAQ:ANIP): JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. The brokerage set an “overweight” rating and a $85.00 price target on the specialty pharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a […] - 2025-03-14 04:34:45
Illinois Municipal Retirement Fund Decreases Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP): Illinois Municipal Retirement Fund lowered its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 8.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,533 shares of the specialty pharmaceutical company’s stock after selling 799 shares during the quarter. Illinois Municipal Retirement Fund’s […] - 2025-03-05 08:46:59
ANI Pharmaceuticals (NASDAQ:ANIP) Cut to Sell at StockNews.com: StockNews.com downgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) from a hold rating to a sell rating in a report released on Monday morning. ANIP has been the subject of several other research reports. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an […] - 2025-03-04 04:50:49
Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $77.71: Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) have been given an average rating of “Buy” by the eight research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy […] - 2025-02-18 04:13:03

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) ANIP holdings

Date	Number of ANIP Shares Held	Base Market Value of ANIP Shares	Local Market Value of ANIP Shares	Change in ANIP Shares Held	Change in ANIP Base Value	Current Price per ANIP Share Held	Previous Price per ANIP Share Held
2025-12-03 (Wednesday)	15,081	USD 1,246,746	USD 1,246,746
2025-12-02 (Tuesday)	15,081	USD 1,238,452	USD 1,238,452	540	USD 10,174	USD 82.12	USD 84.47
2025-12-01 (Monday)	14,541	USD 1,228,278	USD 1,228,278	0	USD -5,526	USD 84.47	USD 84.85
2025-11-28 (Friday)	14,541	USD 1,233,804	USD 1,233,804	36	USD 10,162	USD 84.85	USD 84.36
2025-11-27 (Thursday)	14,505	USD 1,223,642	USD 1,223,642	0	USD 0	USD 84.36	USD 84.36
2025-11-26 (Wednesday)	14,505	USD 1,223,642	USD 1,223,642	108	USD 25,524	USD 84.36	USD 83.22
2025-11-25 (Tuesday)	14,397	USD 1,198,118	USD 1,198,118	180	USD 46,825	USD 83.22	USD 80.98
2025-11-24 (Monday)	14,217	USD 1,151,293	USD 1,151,293	36	USD 20,784	USD 80.98	USD 79.72
2025-11-21 (Friday)	14,181	USD 1,130,509	USD 1,130,509	0	USD 17,017	USD 79.72	USD 78.52
2025-11-20 (Thursday)	14,181	USD 1,113,492	USD 1,113,492	-144	USD -37,235	USD 78.52	USD 80.33
2025-11-19 (Wednesday)	14,325	USD 1,150,727	USD 1,150,727	36	USD -7,682	USD 80.33	USD 81.07
2025-11-18 (Tuesday)	14,289	USD 1,158,409	USD 1,158,409	216	USD 4,845	USD 81.07	USD 81.97
2025-11-17 (Monday)	14,073	USD 1,153,564	USD 1,153,564	72	USD -22,800	USD 81.97	USD 84.02

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ANIP by Blackrock for IE00BYXG2H39

Show aggregate share trades of ANIP

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-02 BUY 540 84.650 81.860 82.139 USD 44,355 68.90
2025-11-28 BUY 36 85.070 83.025 83.229 USD 2,996 68.75
2025-11-26 BUY 108 85.238 82.950 83.179 USD 8,983 68.60
2025-11-26 BUY 108 85.238 82.950 83.179 USD 8,983 68.60
2025-11-25 BUY 180 84.673 81.540 81.853 USD 14,734 68.53
2025-11-24 BUY 36 81.550 78.402 78.717 USD 2,834 68.47
2025-11-20 SELL -144 82.120 78.150 78.547 USD -11,311 68.37 Loss of -1,465 on sale
2025-11-19 BUY 36 81.590 79.055 79.308 USD 2,855 68.31
2025-11-18 BUY 216 82.810 80.950 81.136 USD 17,525 68.25
2025-11-17 BUY 72 85.170 81.680 82.029 USD 5,906 68.18
2025-11-14 BUY 36 85.040 83.740 83.870 USD 3,019 68.10
2025-11-12 BUY 36 89.570 87.210 87.446 USD 3,148 67.93
2025-11-10 BUY 36 90.870 81.820 82.725 USD 2,978 67.72
2025-11-06 BUY 36 94.456 90.040 90.482 USD 3,257 67.48
2025-11-04 BUY 36 95.120 92.370 92.645 USD 3,335 67.22
2025-10-30 BUY 180 93.460 91.665 91.845 USD 16,532 66.82
2025-10-29 BUY 72 92.230 93.800 93.643 USD 6,742 66.69
2025-10-22 SELL -144 93.760 95.830 95.623 USD -13,770 65.96 Loss of -4,272 on sale
2025-10-20 BUY 72 95.120 95.670 95.615 USD 6,884 65.64
2025-10-17 BUY 180 94.790 95.940 95.825 USD 17,249 65.48
2025-10-15 BUY 288 90.100 90.610 90.559 USD 26,081 65.34
2025-10-03 BUY 252 89.640 92.520 92.232 USD 23,242 65.07
2025-10-02 BUY 36 89.130 90.620 90.471 USD 3,257 64.94
2025-09-30 BUY 72 91.600 93.210 93.049 USD 6,700 64.64
2025-09-26 BUY 72 93.050 94.770 94.598 USD 6,811 64.32
2025-09-25 BUY 72 93.370 95.120 94.945 USD 6,836 64.16
2025-09-24 SELL -867 94.990 96.530 96.376 USD -83,558 63.98 Loss of -28,090 on sale
2025-09-18 BUY 38 97.480 98.550 98.443 USD 3,741 63.78
2025-09-17 BUY 114 95.360 98.450 98.141 USD 11,188 63.59
2025-08-20 SELL -152 90.620 90.860 90.836 USD -13,807 62.88 Loss of -4,249 on sale
2025-07-30 BUY 653 64.030 66.390 66.154 USD 43,199 62.21
2025-07-17 SELL -74 68.040 68.390 68.355 USD -5,058 61.96 Loss of -473 on sale
2025-07-11 SELL -296 64.960 66.010 65.905 USD -19,508 61.87 Loss of -1,194 on sale
2025-07-07 BUY 111 64.910 66.180 66.053 USD 7,332 61.77
2025-07-02 BUY 2,035 65.220 65.550 65.517 USD 133,327 61.72
2025-06-11 BUY 74 62.780 63.700 63.608 USD 4,707 61.60
2025-06-10 BUY 74 62.870 64.450 64.292 USD 4,758 61.59
2025-06-04 SELL -37 60.870 62.100 61.977 USD -2,293 61.60 Loss of -14 on sale
2025-04-23 BUY 37 68.370 70.300 70.107 USD 2,594 60.77
2025-04-10 SELL -296 65.120 66.000 65.912 USD -19,510 59.99 Loss of -1,752 on sale
2025-04-08 SELL -37 63.050 68.350 67.820 USD -2,509 59.89 Loss of -293 on sale
2025-04-07 SELL -37 66.990 68.820 68.637 USD -2,540 59.81 Loss of -327 on sale
2025-04-04 SELL -185 67.520 68.400 68.312 USD -12,638 59.72 Loss of -1,590 on sale
2025-04-01 BUY 490 68.020 68.960 68.866 USD 33,744 59.50
2025-03-31 SELL -108 66.950 67.800 67.715 USD -7,313 59.41 Loss of -897 on sale
2025-03-21 BUY 815 64.260 65.510 65.385 USD 53,289 58.84
2025-03-14 SELL -528 62.490 63.600 63.489 USD -33,522 58.47 Loss of -2,649 on sale
2025-03-07 SELL -66 60.620 62.760 62.546 USD -4,128 58.27 Loss of -282 on sale
2025-03-04 SELL -33 59.130 62.000 61.713 USD -2,037 58.19 Loss of -116 on sale
2025-02-25 BUY 66 54.510 56.030 55.878 USD 3,688 58.31
2025-02-19 SELL -33 59.990 60.540 60.485 USD -1,996 58.31 Loss of -72 on sale
2025-02-13 BUY 99 59.190 59.540 59.505 USD 5,891 58.26
2025-02-12 BUY 33 59.680 60.020 59.986 USD 1,980 58.23
2025-02-11 BUY 132 59.850 60.680 60.597 USD 7,999 58.19
2024-12-30 SELL -1,210 54.210 54.450 54.426 USD -65,855 57.96 Profit of 4,271 on sale
2024-11-18 SELL -540 55.250 57.200 57.005 USD -30,783 58.72 Profit of 924 on sale
2024-11-08 SELL -36 61.440 62.270 62.187 USD -2,239 58.36 Loss of -138 on sale
2024-10-21 SELL -36 59.280 60.350 60.243 USD -2,169 0.00 Loss of -2,169 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-02	BUY	540	84.650	81.860	82.139	USD 44,355	68.90
2025-11-28	BUY	36	85.070	83.025	83.229	USD 2,996	68.75
2025-11-26	BUY	108	85.238	82.950	83.179	USD 8,983	68.60
2025-11-26	BUY	108	85.238	82.950	83.179	USD 8,983	68.60
2025-11-25	BUY	180	84.673	81.540	81.853	USD 14,734	68.53
2025-11-24	BUY	36	81.550	78.402	78.717	USD 2,834	68.47
2025-11-20	SELL	-144	82.120	78.150	78.547	USD -11,311	68.37 Loss of -1,465 on sale
2025-11-19	BUY	36	81.590	79.055	79.308	USD 2,855	68.31
2025-11-18	BUY	216	82.810	80.950	81.136	USD 17,525	68.25
2025-11-17	BUY	72	85.170	81.680	82.029	USD 5,906	68.18
2025-11-14	BUY	36	85.040	83.740	83.870	USD 3,019	68.10
2025-11-12	BUY	36	89.570	87.210	87.446	USD 3,148	67.93
2025-11-10	BUY	36	90.870	81.820	82.725	USD 2,978	67.72
2025-11-06	BUY	36	94.456	90.040	90.482	USD 3,257	67.48
2025-11-04	BUY	36	95.120	92.370	92.645	USD 3,335	67.22
2025-10-30	BUY	180	93.460	91.665	91.845	USD 16,532	66.82
2025-10-29	BUY	72	92.230	93.800	93.643	USD 6,742	66.69
2025-10-22	SELL	-144	93.760	95.830	95.623	USD -13,770	65.96 Loss of -4,272 on sale
2025-10-20	BUY	72	95.120	95.670	95.615	USD 6,884	65.64
2025-10-17	BUY	180	94.790	95.940	95.825	USD 17,249	65.48
2025-10-15	BUY	288	90.100	90.610	90.559	USD 26,081	65.34
2025-10-03	BUY	252	89.640	92.520	92.232	USD 23,242	65.07
2025-10-02	BUY	36	89.130	90.620	90.471	USD 3,257	64.94
2025-09-30	BUY	72	91.600	93.210	93.049	USD 6,700	64.64
2025-09-26	BUY	72	93.050	94.770	94.598	USD 6,811	64.32
2025-09-25	BUY	72	93.370	95.120	94.945	USD 6,836	64.16
2025-09-24	SELL	-867	94.990	96.530	96.376	USD -83,558	63.98 Loss of -28,090 on sale
2025-09-18	BUY	38	97.480	98.550	98.443	USD 3,741	63.78
2025-09-17	BUY	114	95.360	98.450	98.141	USD 11,188	63.59
2025-08-20	SELL	-152	90.620	90.860	90.836	USD -13,807	62.88 Loss of -4,249 on sale
2025-07-30	BUY	653	64.030	66.390	66.154	USD 43,199	62.21
2025-07-17	SELL	-74	68.040	68.390	68.355	USD -5,058	61.96 Loss of -473 on sale
2025-07-11	SELL	-296	64.960	66.010	65.905	USD -19,508	61.87 Loss of -1,194 on sale
2025-07-07	BUY	111	64.910	66.180	66.053	USD 7,332	61.77
2025-07-02	BUY	2,035	65.220	65.550	65.517	USD 133,327	61.72
2025-06-11	BUY	74	62.780	63.700	63.608	USD 4,707	61.60
2025-06-10	BUY	74	62.870	64.450	64.292	USD 4,758	61.59
2025-06-04	SELL	-37	60.870	62.100	61.977	USD -2,293	61.60 Loss of -14 on sale
2025-04-23	BUY	37	68.370	70.300	70.107	USD 2,594	60.77
2025-04-10	SELL	-296	65.120	66.000	65.912	USD -19,510	59.99 Loss of -1,752 on sale
2025-04-08	SELL	-37	63.050	68.350	67.820	USD -2,509	59.89 Loss of -293 on sale
2025-04-07	SELL	-37	66.990	68.820	68.637	USD -2,540	59.81 Loss of -327 on sale
2025-04-04	SELL	-185	67.520	68.400	68.312	USD -12,638	59.72 Loss of -1,590 on sale
2025-04-01	BUY	490	68.020	68.960	68.866	USD 33,744	59.50
2025-03-31	SELL	-108	66.950	67.800	67.715	USD -7,313	59.41 Loss of -897 on sale
2025-03-21	BUY	815	64.260	65.510	65.385	USD 53,289	58.84
2025-03-14	SELL	-528	62.490	63.600	63.489	USD -33,522	58.47 Loss of -2,649 on sale
2025-03-07	SELL	-66	60.620	62.760	62.546	USD -4,128	58.27 Loss of -282 on sale
2025-03-04	SELL	-33	59.130	62.000	61.713	USD -2,037	58.19 Loss of -116 on sale
2025-02-25	BUY	66	54.510	56.030	55.878	USD 3,688	58.31
2025-02-19	SELL	-33	59.990	60.540	60.485	USD -1,996	58.31 Loss of -72 on sale
2025-02-13	BUY	99	59.190	59.540	59.505	USD 5,891	58.26
2025-02-12	BUY	33	59.680	60.020	59.986	USD 1,980	58.23
2025-02-11	BUY	132	59.850	60.680	60.597	USD 7,999	58.19
2024-12-30	SELL	-1,210	54.210	54.450	54.426	USD -65,855	57.96 Profit of 4,271 on sale
2024-11-18	SELL	-540	55.250	57.200	57.005	USD -30,783	58.72 Profit of 924 on sale
2024-11-08	SELL	-36	61.440	62.270	62.187	USD -2,239	58.36 Loss of -138 on sale
2024-10-21	SELL	-36	59.280	60.350	60.243	USD -2,169	0.00 Loss of -2,169 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ANIP

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	41,035	0	62,694	65.5%
2025-09-18	72,433	15,812	127,366	56.9%
2025-09-17	122,191	3,115	207,456	58.9%
2025-09-16	35,757	0	163,997	21.8%
2025-09-15	78,192	12	144,940	53.9%
2025-09-12	30,941	0	65,762	47.0%
2025-09-11	39,419	0	128,054	30.8%
2025-09-10	72,168	58	132,797	54.3%
2025-09-09	142,073	160	263,395	53.9%
2025-09-08	35,490	0	162,390	21.9%
2025-09-05	51,458	50	145,846	35.3%
2025-09-04	65,824	100	152,241	43.2%
2025-09-03	62,176	0	181,210	34.3%
2025-09-02	44,473	0	124,889	35.6%
2025-08-29	40,674	250	93,992	43.3%
2025-08-28	99,168	0	164,698	60.2%
2025-08-27	29,327	100	90,650	32.4%
2025-08-26	65,777	0	199,758	32.9%
2025-08-25	37,903	364	120,275	31.5%
2025-08-22	58,262	65	139,885	41.6%
2025-08-21	69,041	150	233,240	29.6%
2025-08-20	40,298	0	144,832	27.8%
2025-08-19	128,579	0	350,791	36.7%
2025-08-18	72,497	100	270,478	26.8%
2025-08-15	63,290	0	374,913	16.9%
2025-08-14	91,445	8,700	225,232	40.6%
2025-08-13	105,535	4,110	254,501	41.5%
2025-08-12	176,947	29,770	533,070	33.2%
2025-08-11	231,265	5,230	706,298	32.7%
2025-08-08	294,255	16,527	803,623	36.6%
2025-08-07	220,706	185	397,616	55.5%
2025-08-06	294,168	0	430,474	68.3%
2025-08-05	48,125	0	71,575	67.2%
2025-08-04	35,419	0	53,139	66.7%
2025-08-01	59,471	0	92,374	64.4%
2025-07-31	47,901	0	84,852	56.5%
2025-07-30	45,147	0	95,248	47.4%
2025-07-29	109,813	0	199,726	55.0%
2025-07-28	74,149	0	114,226	64.9%
2025-07-25	101,383	0	158,638	63.9%
2025-07-24	80,032	0	117,731	68.0%
2025-07-23	88,661	0	122,059	72.6%
2025-07-22	57,120	1,845	70,264	81.3%
2025-07-21	59,264	0	141,593	41.9%
2025-07-18	73,816	200	109,091	67.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	BTEC(USD) LSE
ETF Ticker	BTEK(GBP) LSE
ETF Ticker	2B70(EUR) F
ETF Ticker	2B70.DE(EUR) CXE
ETF Ticker	BTEC.LS(USD) CXE
ETF Ticker	BTEK.LS(GBP) CXE
ETF Ticker	BTEC.L(GBP) LSE
ETF Ticker	BTEK.L(GBP) LSE